Daily Stock Analysis, CERS, Cerus Corp, priceseries

Cerus Corp. Daily Stock Analysis
Stock Information
Open
4.37
Close
4.47
High
4.53
Low
4.33
Previous Close
4.34
Daily Price Gain
0.13
YTD High
6.88
YTD High Date
Mar 1, 2019
YTD Low
3.95
YTD Low Date
Nov 11, 2019
YTD Price Change
-0.87
YTD Gain
-16.29%
52 Week High
6.88
52 Week High Date
Mar 1, 2019
52 Week Low
3.95
52 Week Low Date
Nov 11, 2019
52 Week Price Change
-0.81
52 Week Gain
-15.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2018
3.59
Jan 16. 2018
4.06
8 Trading Days
13.21%
Link
LONG
Jan 22. 2018
4.19
Jan 31. 2018
4.52
7 Trading Days
7.96%
Link
LONG
Feb 28. 2018
4.28
Mar 27. 2018
5.28
19 Trading Days
23.30%
Link
LONG
Feb 11. 2019
5.94
Feb 26. 2019
6.32
10 Trading Days
6.45%
Link
LONG
Jun 27. 2019
4.94
Aug 1. 2019
5.69
24 Trading Days
15.17%
Link
Company Information
Stock Symbol
CERS
Exchange
NasdaqGM
Company URL
http://www.cerus.com
Company Phone
9252886000
CEO
William Mariner Greenman
Headquarters
California
Business Address
2550 STANWELL DRIVE, CONCORD, CA 94520
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001020214
About

Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. It produces blood system for platelets and plasma. It markets its products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Description

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.